Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
F-star Therapeutics, Inc. (SBPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: "F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update"
11/10/2021 8-K Quarterly results
Docs: "F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., November 10, 2021 - F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced third quarter 2021 financial results and a corporate update. Eliot Forster, CEO of F-star Therapeutics, Inc., said, “A year on from listing on NASDAQ, we have delivered on our planned milestones, and through them value for patients, partners and our investors. Our agile, tenacious approach, working with world-leading investigators, continues to further F-star’s mission to b...",
"H2 2021 H1 2022 H2 2022 H2 2023 H1 2023 FS222 FS120 SB 11285 FS118"
08/12/2021 8-K Quarterly results
Docs: "F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., August 12, 2021 — F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces second quarter 2021 financial results and provides a corporate update. The Company today announces an expanded clinical development strategy for FS118, F-star's first-in-class bispecific antibody targeting LAG-3 and PD-L1, into checkpoint inhibitor naïve patients. This new study with FS118 is in biomarker enriched subsets of patients with non-small cell lung cancer and diffuse...",
"Slides"
05/17/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
Docs: "F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, UK and CAMBRIDGE, MA, March 29, 2021 — F-star Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces 2020 full-year financial results and provides corporate update. 2020 was a year of transformation for F-star. The Company successfully listed on NASDAQ and advanced multiple programs into the clinic. F-star also presented Phase 1 data on its most advanced program FS118, and dosed patients in two additional clinical trials with FS222 and FS120. The Company continued to deliver on its long-term collaborations and e..."
04/27/2018 8-K Quarterly results
Docs: "Presented expanded inarigivir data from the ACHIEVE trial at the annual meeting of the European Association for the Study of the Liver in Paris, France o Highlighted combined results from the 24-week trial of both the 25mg and 50mg cohorts of Part A of the ongoing Phase 2 ACHIEVE trial examining the use of inarigivir soproxil followed by Viread® for the treatment of chronic hepatitis B virus o Demonstrated significant reductions in viral markers, including HBV DNA, HBV RNA and HBsAg with favorable safety and tolerability profiles ➢ Presented 12 and 24-week inarigivir data from the ACHIEVE trial at the annual meeting of the Asian Pacific Association for the Study of the Liver in New Delhi, India ➢ Continued to progress the IND and CTA-enabling programs for SB 11285 with the go..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy